Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Although genetic factors contribute to almost half of all cases of deafness, treatment options for genetic deafness are limited. We developed a genome-editing approach to target a dominantly inherited form of genetic deafness. Here we show that cationic lipid-mediated in vivo delivery of Cas9-guide RNA complexes can ameliorate hearing loss in a mouse model of human genetic deafness. We designed and validated, both in vitro and in primary fibroblasts, genome editing agents that preferentially disrupt the dominant deafness-associated allele in the Tmc1 (transmembrane channel-like gene family 1) Beethoven (Bth) mouse model, even though the mutant Tmc1 Bth allele differs from the wild-type allele at only a single base pair. Injection of Cas9-guide RNA-lipid complexes targeting the Tmc1 Bth allele into the cochlea of neonatal Tmc1 Bth/+ mice substantially reduced progressive hearing loss. We observed higher hair cell survival rates and lower auditory brainstem response thresholds in injected ears than in uninjected ears or ears injected with control complexes that targeted an unrelated gene. Enhanced acoustic startle responses were observed among injected compared to uninjected Tmc1 Bth/+ mice. These findings suggest that protein-RNA complex delivery of target gene-disrupting agents in vivo is a potential strategy for the treatment of some types of autosomal-dominant hearing loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, lipid-mediated nanoparticle (LNP) delivery has been used to transport CRISPR-Cas components in the form of either mRNA/sgRNA or preassembled RNPs into tissues 71-74 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [74]
In the citing paper
“Additionally, lower auditory response thresholds and improved acoustic responses were observed in injected mice.[226]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [226]
In the citing paper
“The intraaural injection of Cas9 RNPs/lipofectamine 2000 complexes into the scala media of neonatal Tmc1Bth/+ mice significantly increased the survival of hair cells.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [226]
In the citing paper
“All these results demonstrated that this system substantially reduced progressive hearing loss in Beethoven mouse model (Fig. 3B) [113].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 4×
“We identified three candidate sgRNAs (Tmc1-mut1, Tmc1-mut2, and Tmc1-mut3) that place the Bth mutation at position 11, 12, or 15, respectively, of the spacer, counting the PAM as positions 21-23 (Fig.”
InfluentialImproving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“A fourth sgRNA, Tmc1-mut4, is a truncated version of Tmc1-mut3 designed to increase genome editing DNA specificity 22 .”
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Newborn Hearing Screening — A Silent Revolution
Morton, C. C., & Nance, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050700 · Cited by 1,686
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487
Self-citationZuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Self-citationCRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Self-citationLong, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
Self-citationEfficient delivery of genome-editing proteins using bioreducible lipid nanoparticles
Wang, M., Zuris, J. A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Pouli, D., Wu, Q., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520244113 · Cited by 624
Self-citation
Cited by
Items 101–200 of 566
Strategies for In Vivo Genome Editing in Nondividing Cells
Nami, F., Basiri, M., Satarian, L., Curtiss, C., Baharvand, H., & Verfaillie, C. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.03.004 · Cited by 73
Suzuki, K., Yamamoto, M., Hernández‐Benítez, R., Li, Z., Wei, C., Soligalla, R. D., Aizawa, E., Hatanaka, F., Kurita, M., Reddy, P., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0213-0 · Cited by 73
An Update on the Application of CRISPR Technology in Clinical Practice
Morshedzadeh, F., Ghanei, M., Lotfi, M., Ghasemi, M., Ahmadi, M., Najari-Hanjani, P., Sharif, S., Mozaffari‐Jovin, S., Peymani, M., & Abbaszadegan, M. R. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00724-z · Cited by 72
Harnessing lipid nanoparticles for efficient CRISPR delivery
Yan, J., Kang, D. D., & Dong, Y. (2021) · Biomaterials Science · doi:10.1039/d1bm00537e · Cited by 72
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing
Wang, Y., Qi, T., Liu, J., Yang, Y., Wang, Z., Wang, Y., Wang, T., Li, M., Li, M., Lu, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.abo6405 · Cited by 73
Gene Editing and Genotoxicity: Targeting the Off-Targets
Blattner, G., Cavazza, A., Thrasher, A. J., & Turchiano, G. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.613252 · Cited by 70
Preventing autosomal-dominant hearing loss in Bth mice with CRISPR/CasRx-based RNA editing
Zheng, Z., Guo, L., Cui, C., Wang, F., Wang, X., Xu, Z., Guo, H., Chen, Y., Tang, H., Wang, D., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00893-4 · Cited by 70
Self-citationDuan, Y., Tao, Y., Qu, Z., Chen, Y., Miranda, A., Zhou, X., Lok, K.-C., Chen, Y., Fu, A. K. Y., Gradinaru, V., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00759-0 · Cited by 69
Self-citationCurrent status and prospect of ZIF-based materials for breast cancer treatment
Zeng, Y., Liao, D., Kong, X., Huang, Q., Zhong, M., Liu, J., Nezamzadeh‐Ejhieh, A., Pan, Y. H., & Song, H. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113612 · Cited by 69
Chen, J., Hong, F., Zhang, C., Li, L., Wang, C., Shi, H., Fu, Y., & Wang, J. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0967-1 · Cited by 69
Non-viral strategies for delivering genome editing enzymes
Li, J., Røise, J. J., He, M., Das, R., & Murthy, N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.004 · Cited by 68
Diagnosis, Intervention, and Prevention of Genetic Hearing Loss
Yang, T., Guo, L., Wang, L., & Yu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-6123-4_5 · Cited by 68
Khan, M. (2024) · Polymers · doi:10.3390/polym16182629 · Cited by 67
The impact of technology on promoting physical activities and mental health: a gender-based study
Liu, Y., Zhang, H., & Xu, R. (2023) · BMC Psychology · doi:10.1186/s40359-023-01348-3 · Cited by 67
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 66
Self-citationZhang, W., Kim, S. M., Wang, W., Cai, C., Feng, Y., Kong, W., & Lin, X. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00221 · Cited by 65
Self-citationShen, Y., Cohen, J. L., Nicoloro, S. M. C., Kelly, M., Yenilmez, B., Henriques, F. D. S., Tsagkaraki, E., Edwards, Y. J. K., Hu, X., Friedline, R. H., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004554 · Cited by 65
Enhancing gene editing specificity by attenuating DNA cleavage kinetics
Miller, J. C., Patil, D. P., Xia, D. F., Paine, C. B., Fauser, F., Richards, H. W., Shivak, D. A., Bendaña, Y. R., Hinkley, S. J., Scarlott, N. A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0186-z · Cited by 63
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing
Rabinowitz, R., & Offen, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.009 · Cited by 62
Chou, S., Yang, P., Ban, Q., Yang, Y., Wang, M., Chien, C., Chen, S., Sun, N., Zhu, Y., Liu, H., et al. (2020) · Advanced Science · doi:10.1002/advs.201903432 · Cited by 61
Nanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 61
Self-citationGu, X., Chai, R., Guo, L., Dong, B., Li, W., Shu, Y., Huang, X., & Li, H. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00008 · Cited by 61
Self-citationZhang, H., Pan, H., Zhou, C., Wei, Y., Ying, W., Li, S., Wang, G., Li, C., Ren, Y., Li, G., et al. (2018) · Development · doi:10.1242/dev.168906 · Cited by 60
Self-citationNoh, B., Rim, J. H., Gopalappa, R., Lin, H., Kim, K. M., Kang, M. J., Gee, H. Y., Choi, J. Y., Kim, S., & Jung, J. (2022) · Theranostics · doi:10.7150/thno.67781 · Cited by 60
Jo, D. H., Koo, T., Cho, C. S., Kim, J. H., Kim, J.-S., & Kim, J. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.009 · Cited by 57
In the business of base editors: Evolution from bench to bedside
Porto, E. M., & Komor, A. C. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002071 · Cited by 57
Towards the Clinical Application of Gene Therapy for Genetic Inner Ear Diseases
Lahlou, G., Calvet, C., Giorgi, M., Lecomte, M.-J., & Safieddine, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031046 · Cited by 57
Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear
Delaney, D. S., Liew, L. J., Lye, J., Atlas, M. D., & Wong, E. Y. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1207141 · Cited by 58
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424872 · Cited by 55
Zhu, X., Tang, R., Wang, S., Chen, X., Hu, J., Lei, C., Huang, Y., Wang, H., Nie, Z., & Yao, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b09024 · Cited by 55
Self-citationSystematic decomposition of sequence determinants governing CRISPR/Cas9 specificity
Fu, R., He, W., Dou, J., Villarreal, O. D., Bedford, E., Wang, H., Hou, C., Zhang, L., Wang, Y., Ma, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28028-x · Cited by 54
Self-citationMolecular correction of Duchenne muscular dystrophy by splice modulation and gene editing
Hanson, B., Wood, M. J. A., & Roberts, T. C. (2021) · RNA Biology · doi:10.1080/15476286.2021.1874161 · Cited by 54
Tao, Y., Lamas, V., Du, W., Zhu, W., Li, Y., Whittaker, M. N., Zuris, J. A., Thompson, D. B., Rameshbabu, A. P., Shu, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40476-7 · Cited by 54
Self-citationIntracellular delivery of therapeutic proteins. New advancements and future directions
Porello, I., & Cellesi, F. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1211798 · Cited by 54
Peng, H., Zheng, Y., Zhao, Z., Liu, T., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty558 · Cited by 53
Clinical applications of CRISPR‐based genome editing and diagnostics
Foss, D. V., Hochstrasser, M. L., & Wilson, R. C. (2019) · Transfusion · doi:10.1111/trf.15126 · Cited by 53
Reversing Mechanoinductive DSP Expression by CRISPR/dCas9–mediated Epigenome Editing
Qu, J. T., Zhu, L., Zhou, Z., Chen, P., Liu, S., Locy, M. L., Thannickal, V. J., & Zhou, Y. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201711-2242oc · Cited by 53
Cui, C., Wang, D., Huang, B., Wang, F., Chen, Y., Lv, J., Zhang, L., Han, L., Liu, D., Chen, Z., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.016 · Cited by 52
Self-citationNucleic acid nanostructure for delivery of CRISPR/Cas9‐based gene editing system
Tang, W., Liu, J., & Ding, B. (2022) · Interdisciplinary medicine · doi:10.1002/inmd.20220014 · Cited by 52
Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing
Gu, X. G., Wang, D., Xu, Z., Wang, J., Guo, L., Chai, R., Li, G., Shu, Y., & Li, H. (2021) · Genome biology · doi:10.1186/s13059-021-02311-4 · Cited by 52
Self-citationOutlook and future of inner ear therapy
Devare, J., Gubbels, S. P., & Raphael, Y. (2018) · Hearing Research · doi:10.1016/j.heares.2018.05.009 · Cited by 51
Advances in mouse genetics for the study of human disease
Brown, S. D. M. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab153 · Cited by 51
Wang, X., Dong, K., Kong, D., Zhou, Y., Yin, J., Cai, F., Wang, M., & Ye, H. (2021) · Science Advances · doi:10.1126/sciadv.abh2358 · Cited by 51
The Roles of TGF-β Signaling in Cerebrovascular Diseases
Zhang, Y., & Yang, X. Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.567682 · Cited by 51
Exploiting CRISPR Cas9 in Three-Dimensional Stem Cell Cultures to Model Disease
Gopal, S., Rodrigues, A. L., & Dordick, J. S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00692 · Cited by 51
Sun, D., Sun, Z., Jiang, H., Vaidya, A. M., Xin, R., Ayat, N. R., Schilb, A. L., Qiao, P. L., Han, Z., Naderi, A., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00856 · Cited by 49
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 48
Nanotechnology-enabled gene delivery for cancer and other genetic diseases
Jiang, T., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2200246 · Cited by 49
A Nucleic Acid/Gold Nanorod-Based Nanoplatform for Targeted Gene Editing and Combined Tumor Therapy
Tang, W., Han, L., Lu, X., Wang, Z., Liu, F., Li, Y., Liu, S., Liu, S., Tian, R., Liu, J., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c02122 · Cited by 48
Self-citationIdentifying Treatments for Taste and Smell Disorders: Gaps and Opportunities
Mainland, J. D., Barlow, L. A., Munger, S. D., Millar, S. E., Vergara, M. N., Jiang, P., Schwob, J. E., Goldstein, B. J., Boye, S. L., Martens, J. R., et al. (2020) · Chemical Senses · doi:10.1093/chemse/bjaa038 · Cited by 48
Gene therapy for monogenic disorders: challenges, strategies, and perspectives
Zhang, Y., & Wu, Z. (2023) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2023.08.001 · Cited by 47
Bankoti, K., Generotti, C. J., Hwa, T. P., Wang, L., O’Malley, B. W., & Li, D. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.005 · Cited by 47
Allele-specific genome targeting in the development of precision medicine
Wu, J., Tang, B., & Tang, Y. (2020) · Theranostics · doi:10.7150/thno.43298 · Cited by 46
CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy
Wang, D., Chen, L., Chengbi, L., Long, Q., Yang, Q., Huang, A., & Tang, H. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01233-4 · Cited by 46
AAV‐mediated Gene Therapy for Hereditary Deafness: Progress and Perspectives
Zhang, L., Tan, F., Qi, J., Lu, Y., Wang, X., Yang, X., Chen, X., Zhang, X., Fan, J., Zhou, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202402166 · Cited by 46
Self-citationAdvances in genome editing for genetic hearing loss
Ding, N., Lee, S., Lieber-Kotz, M., Yang, J., & Gao, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.001 · Cited by 45
Self-citationFetal antisense oligonucleotide therapy for congenital deafness and vestibular dysfunction
Wang, L., Kempton, J. B., Jiang, H., Jodelka, F. M., Brigande, A. M., Dumont, R. A., Rigo, F., Lentz, J. J., Hastings, M. L., & Brigande, J. V. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa194 · Cited by 45
Approaches and Vectors for Efficient Cochlear Gene Transfer in Adult Mouse Models
Zhao, Y. F., Zhang, L., Wang, D., Chen, B., & Shu, Y. (2022) · Biomolecules · doi:10.3390/biom13010038 · Cited by 45
Self-citationIyer, A. A., & Groves, A. K. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.660748 · Cited by 44
Eshraghi, A. A., Jung, H. D., & Mittal, R. (2019) · The Anatomical Record · doi:10.1002/ar.24107 · Cited by 44
The genetic landscape and possible therapeutics of neurofibromatosis type 2
Ghalavand, M. A., Asghari, A., Farhadi, M. R., Taghizadeh‐Hesary, F., Garshasbi, M., & Falah, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02940-8 · Cited by 43
Nano-vectors for CRISPR/Cas9-mediated genome editing
Yang, P., Lee, A. Y.-T., Xue, J., Chou, S., Lee, C., Tseng, P., Zhang, T. X., Zhu, Y., Lee, J., Chiou, S., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101482 · Cited by 43
Closely related type II-C Cas9 orthologs recognize diverse PAMs
Wei, J., Hou, L., Liu, J., Wang, Z., Gao, S., Qi, T., Gao, S., Sun, S., & Wang, Y. (2022) · eLife · doi:10.7554/elife.77825 · Cited by 42
Advances in CRISPR Delivery Methods: Perspectives and Challenges
Demirci, S., Essawi, K., Germino-Watnick, P., Liu, X., Hakami, W., & Tisdale, J. F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0051 · Cited by 41
Mutation-Dependent Pathomechanisms Determine the Phenotype in the Bestrophinopathies
Nachtigal, A.-L., Milenkovic, A., Brandl, C., Schulz, H. L., Duerr, L. M. J., Lang, G. E., Reiff, C., Herrmann, P., Kellner, U., & Weber, B. H. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051597 · Cited by 41
Li, Y., Li, A. C., & Xu, Q. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800996 · Cited by 41
Self-citationIs there an unmet medical need for improved hearing restoration?
Wolf, B., Kusch, K., Hunniford, V. T., Vona, B., Kühler, R., Keppeler, D., Strenzke, N., & Moser, T. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215798 · Cited by 40
Liu, L., Zou, L., Li, K., Hou, H., Hu, Q., Liu, S., Li, J., Song, C., Chen, J., Wang, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111061 · Cited by 40
SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials
Cai, Q., Guo, R., Chen, D., Deng, Z., & Gao, J. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03254-9 · Cited by 40
Du, W., Ergin, V., Loeb, C., Huang, M., Silver, S., Armstrong, A. M., Huang, Z., Gurumurthy, C. B., Staecker, H., Liu, X. Z., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.05.005 · Cited by 40
Self-citationLipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy
Abaza, T., Mohamed, E., & Zaky, M. Y. (2025) · Medical Oncology · doi:10.1007/s12032-025-02939-3 · Cited by 39
Applications of Lgr5-Positive Cochlear Progenitors (LCPs) to the Study of Hair Cell Differentiation
Lenz, D. R., Gunewardene, N., Abdul‐Aziz, D., Wang, Q., Gibson, T. M., & Edge, A. S. B. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00014 · Cited by 39
The use of nonhuman primates in studies of noise injury and treatment
Burton, J. A., Valero, M. D., Hackett, T. A., & Ramachandran, R. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5132709 · Cited by 39
Cui, C., Wang, S., Wang, D., Zhao, J., Huang, B., Zhu, B., Chen, Y., Tang, H., Han, Y., Cheng, Y., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01235-1 · Cited by 39
Self-citationRaniszewska, A., Vroman, H. H., Dumoulin, D. W., Cornelissen, R., Aerts, J. G. J. V., & Domagala-Kulawik, J. J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02648-y · Cited by 39
Stojković, M., Han, D., Jeong, M., Stojković, P., & Stanković, K. M. (2021) · Stem Cells · doi:10.1002/stem.3353 · Cited by 38
Gene Therapy Restores Auditory Functions in an Adult Vglut3 Knockout Mouse Model
Zhao, X., Liu, H., Liu, H., Cai, R., & Wu, H. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.062 · Cited by 38
Congenital Deafness and Recent Advances Towards Restoring Hearing Loss
Renauld, J. M., & Basch, M. L. (2021) · Current Protocols · doi:10.1002/cpz1.76 · Cited by 38
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Adeno-associated virus gene replacement for recessive inner ear dysfunction: Progress and challenges
Askew, C., & Chien, W. W. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107947 · Cited by 37
Holmgaard, A. B., Askou, A. L., Jensen, E. G., Alsing, S., Bak, R. O., Mikkelsen, J. G., & Corydon, T. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.032 · Cited by 36
A Bump-Hole Approach for Directed RNA Editing
Monteleone, L. R., Matthews, M. M., Palumbo, C. M., Thomas, J. M., Zheng, Y., Chiang, Y., Fisher, A. J., & Beal, P. A. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.025 · Cited by 36
Genome Editing for CNS Disorders
Duarte, F. T., & Déglon, N. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.579062 · Cited by 36
Li, Y., Zhao, X., Hu, Y., Sun, H., He, Z., Yuan, J., Cai, H. “., Sun, Y., Huang, X., Kong, W., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3907 · Cited by 36
Self-citationA Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome
French, L. S., Mellough, C., Chen, F. K., & Carvalho, L. S. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00183 · Cited by 36
Rescue of hearing by adenine base editing in a humanized mouse model of Usher syndrome type 1F
Peters, C. W., Hanlon, K. S., Ivanchenko, M. V., Zinn, E. M., Linarte, E., Li, Y., Levy, J. M., Liu, D. R., Kleinstiver, B. P., Indzhykulian, A. A., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.007 · Cited by 36
Self-citationGenome and base editing for genetic hearing loss
Niggemann, P., György, B., & Chen, Z. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107958 · Cited by 36
Self-citationCRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss
Farooq, R., Hussain, K., Tariq, M., Farooq, A., & Mustafa, M. (2020) · Journal of Applied Genetics · doi:10.1007/s13353-019-00535-6 · Cited by 36
CRISPR/Cas9-mediated correction of mutated copper transporter ATP7B
Pöhler, M., Guttmann, S., Nadzemova, O., Lenders, M., Brand, E., Zibert, A., Schmidt, H., & Sandfort, V. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239411 · Cited by 35
Qiao, J., Li, W., Lin, S., Sun, W., Ma, L., & Liu, Y. (2019) · Communications Biology · doi:10.1038/s42003-019-0402-x · Cited by 34
Zhu, W., Du, W., Rameshbabu, A. P., Armstrong, A. M., Silver, S., Kim, Y., Wei, W., Shu, Y., Liu, X., Lewis, M. A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn0689 · Cited by 34
Self-citationStem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art
Nourbakhsh, A., Colbert, B., Nisenbaum, E., El-Amraoui, A., Dykxhoorn, D. M., Koehler, K. R., Chen, Z., & Liu, X. Z. (2021) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-020-00781-0 · Cited by 34
Self-citationHearing consequences in Gjb2 knock-in mice: implications for human p.V37I mutation
Lin, X., Li, G., Zhang, Y., Zhao, J., Lu, J., Gao, Y., Liu, H., Li, G., Yang, T., Song, L., et al. (2019) · Aging · doi:10.18632/aging.102246 · Cited by 34
Advancements in prevention and intervention of sensorineural hearing loss
Ren, H., Hu, B., & Jiang, G. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221104987 · Cited by 34
In Vivo Assessment of Potential Therapeutic Approaches for USH2A-Associated Diseases
Pendse, N. D., Lamas, V., Pawlyk, B. S., Maeder, M. L., Chen, Z., Pierce, E. A., & Liu, Q. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_15 · Cited by 34
Self-citationChristie, K. A., Robertson, L. J., Conway, C., Blighe, K., DeDionisio, L., Chao-Shern, C., Kowalczyk, A. M., Marshall, J., Turnbull, D. M., Nesbit, M. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.002 · Cited by 33
Li, Y., Li, P., Li, R., & Xu, Q. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000178 · Cited by 33
Self-citationThe potential of gene editing for Huntington’s disease
Duan, W., Urani, E., & Mattson, M. P. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.02.005 · Cited by 33
Metadata
- Authors
- Gao, X., Tao, Y., Lamas, V., Huang, M., Yeh, W.-H., Pan, B., Hu, Y.-J., Hu, J. H., Thompson, D. B., Shu, Y., Li, Y., Wang, H., Yang, S., Xu, Q., Polley, D. B., Liberman, M. C., Kong, W.-J., Holt, J. R., Chen, Z.-Y., & Liu, D. R.
- Affiliations
- Broad Institute (US)
- Massachusetts Eye and Ear Infirmary (US)
- Boston Children's Hospital (US)
- Howard Hughes Medical Institute (US)
- Tufts University (US)
- Corresponding author
- Chen, Zheng-Yi
- Liu, David R.
- ORCID
- Venue
- Nature
- Published
- 2017-12-20
- Volume
- 553
- Issue
- 7687
- Pages
- 217-221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5784267
- OpenAlex
- W2778806019
- Cited by
- 536
- References
- 28
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 58 · 2023: 62 · 2022: 64 · 2021: 60 · 2020: 101 · 2019: 67 · 2018: 54 · 2017: 1
- FWCI
- 37.88
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (2r01dc013521-11a1)
- National Institute on Deafness and Other Communication Disorders (R01-DC013521, R01DC009836, P30DC005209, R01DC006908, F32DC000138, R01DC000188)
- National Institute of General Medical Sciences (R35GM118062)
- National Institute of Biomedical Imaging and Bioengineering (R01EB022376)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD090255)
- Topics
- Life Sciences › Neuroscience › Sensory Systems › Hearing, Cochlea, Tinnitus, Genetics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- autosomal dominant hearing loss, CRISPR/Cas9 genome editing, in vivo gene delivery, dominant negative mutation, auditory brainstem response, acoustic startle response
- MeSH terms
- Gene Editing, Acoustic Stimulation, Alleles, Animals, Animals, Newborn, Auditory Threshold, Base Sequence, Cell Survival, Cochlea, Disease Models, Animal, Female, Fibroblasts, Genes, Dominant, Hair Cells, Auditory, Humans, Liposomes, Male, Membrane Proteins, Reflex, Startle, Genetic Therapy, Evoked Potentials, Auditory, Brain Stem, Hearing Loss, Mice, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.